https://nxtin.health/2026/11/12/biomatter-raises-18m-series-a-to-scale-its-ai-powered-enzyme-design-for-global-industry-leaders/ 2026-11-12T06:51:49Z NXTin health en Biomatter raises $18M series A to scale its AI-powered enzyme design for global industry leaders 2026-11-12T06:48:29Z Blog https://nxtin.health/2026/11/11/coloplast-opens-new-factory-in-portugal-to-support-global-growth/ 2026-11-11T14:59:23Z NXTin health en Coloplast opens new factory in Portugal to support global growth 2026-11-11T14:59:20Z Blog https://nxtin.health/2026/11/11/cyprus-approves-national-blood-strategy-to-modernise-blood-services/ 2026-11-11T14:49:50Z NXTin health en Cyprus approves National Blood Strategy to modernise blood services 2026-11-11T14:49:48Z Blog https://nxtin.health/2026/11/11/switchpoint-bio-raises-5-3m-pre-seed-to-make-treatment-response-visible-from-blood/ 2026-11-11T14:27:01Z NXTin health en Switchpoint Bio raises $5.3M pre-seed to make treatment response visible from blood 2026-11-11T14:26:59Z Blog https://nxtin.health/2026/11/11/paolo-will-hear-his-childrens-voices-again-a-pioneering-robotic-procedure-at-policlinico-di-milano/ 2026-11-11T10:04:35Z NXTin health en Paolo will hear his children's voices again - a pioneering robotic procedure at Policlinico di Milano 2026-11-11T10:04:34Z Blog https://nxtin.health/2026/11/11/giving-the-voice-a-face-semmelweis-researchers-use-virtual-avatars-to-help-patients-with-schizophrenia/ 2026-11-11T09:53:32Z NXTin health en Giving the voice a face: Semmelweis researchers use virtual avatars to help patients with schizophrenia 2026-11-11T09:01:40Z Blog https://nxtin.health/2026/11/11/2026-access-to-medicine-index/ 2026-11-11T08:49:34Z NXTin health en 2026 Access to Medicine index 2026-11-11T08:49:32Z Blog https://nxtin.health/2026/11/11/portugal-involved-in-one-third-of-clinical-trials-selected-for-europes-fast-eu-initiative/ 2026-11-12T06:30:00Z NXTin health en Portugal involved in one-third of clinical trials selected for Europe's FAST-EU initiative 2026-11-11T03:06:00Z Blog https://nxtin.health/2026/11/10/princess-maxima-center-launches-long-term-collaboration-with-two-centers-in-bulgaria/ 2026-11-10T19:23:20Z NXTin health en Princess Máxima Center launches long-term collaboration with two centers in Bulgaria 2026-11-10T19:23:17Z Blog https://nxtin.health/2026/11/10/formycon-and-biocelys-combine-complementary-development-and-manufacturing-expertise-in-new-biosimilar-project-fyb286/ 2026-11-10T19:12:52Z NXTin health en Formycon and Biocelys combine complementary development and manufacturing expertise in new biosimilar project FYB286 2026-11-10T19:12:49Z Blog https://nxtin.health/2026/11/10/denmarks-ai-supercomputer-gefion-enters-next-chapter-strengthening-responsible-and-sovereign-ai-with-new-ownership-and-dkk-500-million-investment/ 2026-11-10T19:12:39Z NXTin health en Denmark’s AI supercomputer Gefion enters next chapter strengthening responsible and sovereign AI with new ownership and DKK 500 million investment 2026-11-10T18:47:36Z Blog https://nxtin.health/2026/11/10/a-heartfelt-recognition-meet-the-lundbeck-foundation-talent-prize-laureate-2026/ 2026-11-10T12:21:17Z NXTin health en A heartfelt recognition - meet the Lundbeck Foundation Talent prize laureate 2026! 2026-11-10T12:10:54Z Blog https://nxtin.health/2026/11/10/rna-made-in-europe-unpacking-the-potential/ 2026-11-10T10:29:41Z NXTin health en RNA - Made in Europe. Unpacking the potential 2026-11-10T10:26:05Z Blog https://nxtin.health/2026/11/10/india-netherlands-medtech-roadshow/ 2026-11-10T10:08:11Z NXTin health en India–Netherlands MedTech roadshow 2026-11-10T10:07:31Z Blog https://nxtin.health/2026/11/10/who-european-region-2027-summer-school-on-ncd-prevention-and-healthy-ageing-call-for-applications/ 2026-11-10T07:18:28Z NXTin health en WHO European Region: 2027 Summer School on NCD Prevention and Healthy Ageing. Call for applications 2026-11-10T07:18:26Z Blog https://nxtin.health/2026/11/10/anaheim-bio-launches-with-e40m-series-a-financing-to-advance-ana-1-for-calcium-pyrophosphate-deposition-disease-into-the-clinic/ 2026-11-10T07:12:45Z NXTin health en Anaheim Bio launches with €40M Series A financing to advance ANA-1 for calcium pyrophosphate deposition disease into the clinic 2026-11-10T07:01:40Z Blog https://nxtin.health/2026/11/10/desentums-upsit-study-with-birch-pollen-allergy-treatment-dm-101px-approved-by-paul-ehrlich-institut-in-germany/ 2026-11-10T06:36:48Z NXTin health en Desentum’s UPSIT study with birch pollen allergy treatment DM-101PX approved by Paul-Ehrlich-Institut in Germany 2026-11-10T06:36:45Z Blog